Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial

Benjamin L Maughan, Sumanta K Pal, David Gill, Kenneth Boucher, Christopher Martin, Meghan Salgia, Roberto Nussenzveig, Ting Liu, Josiah L Hawks, Julia Batten, Gayatri Nachaegari, Robert Stephenson, William Lowrance, Jeremy Jones, Christopher Dechet, Neeraj Agarwal, Benjamin L Maughan, Sumanta K Pal, David Gill, Kenneth Boucher, Christopher Martin, Meghan Salgia, Roberto Nussenzveig, Ting Liu, Josiah L Hawks, Julia Batten, Gayatri Nachaegari, Robert Stephenson, William Lowrance, Jeremy Jones, Christopher Dechet, Neeraj Agarwal

Abstract

Lessons learned: Pazopanib was not effective in altering the premetastatic niche in the neoadjuvant setting.Pazopanib was safe and well tolerated without any new safety signals.

Background: Vascular endothelial growth factor receptor 1 (VEGFR1) expressing myeloid-derived suppressor cells (VEGFR1+ MDSCs) potentially foster metastases by establishing a premetastatic niche. In a preclinical study, VEGFR1+ clustering in lymph nodes (LNs) independently predicted time to biochemical recurrence (TTBR) in localized prostate cancer [1]. The hypothesis was that neoadjuvant pazopanib therapy will decrease VEGFR1+ clusters in pelvic lymph nodes and improve outcomes.

Methods: This is a phase II trial (NCT01832259) of neoadjuvant pazopanib 800 mg versus placebo daily for 4 weeks in high-risk localized prostate cancer. The primary endpoint was a decrease in VEGFR1+ MDSC clustering assessed by immunohistochemistry (IHC) analysis. Secondary endpoints were safety, feasibility, and TTBR.

Results: Thirty patients were randomized to pazopanib versus placebo, with 15 patients randomized to each arm. Demographic and disease characteristics were similar in both arms. There was no difference in the VEGFR1+ clustering between the treatment arms (p = .345). Neoadjuvant therapy with pazopanib was well tolerated, and surgical complications were similar in both arms.

Conclusion: Neoadjuvant pazopanib therapy did not alter the premetastatic niche; however, treatment targeting vascular endothelial growth factor (VEGF) in the preoperative period was safe and feasible, which may open up the avenue to investigate novel combinatorial regimens, including a VEGF inhibitor in combination with immune checkpoint inhibitor in this setting.

© AlphaMed Press; the data published online to support this summary is the property of the authors.

Figures

Figure 1.
Figure 1.
Formalin‐fixed paraffin‐embedded section of the benign pelvic lymph node showing vascular endothelial growth factor receptor 1‐positive cell clusters (immunohistochemistry, ×10 and ×40 resolution).

References

    1. Pal SK, Vuong W, Zhang W et al. Clinical and translational assessment of VEGFR1 as a mediator of the premetastatic niche in high‐risk localized prostate cancer. Mol Cancer Ther 2015;14:2896–2900.
    1. Langley RR, Fidler IJ. The seed and soil hypothesis revisited—The role of tumor‐stroma interactions in metastasis to different organs. Int J Cancer 2011;128:2527–2535.
    1. Hiratsuka S, Nakamura K, Iwai S et al. Mmp9 induction by vascular endothelial growth factor receptor‐1 is involved in lung‐specific metastasis. Cancer Cell 2002;2:289–300.
    1. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1‐positive haematopoietic bone marrow progenitors initiate the pre‐metastatic niche. Nature 2005;438:820.
    1. Fujita K, Nakayama M, Nakai Y et al. Vascular endothelial growth factor receptor 1 expression in pelvic lymph nodes predicts the risk of cancer progression after radical prostatectomy. Cancer Sci 2009;100:1047–1050.
    1. Hussain M, Tangen CM, Thompson IM, Jr. et al. Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high‐risk prostate cancer after radical prostatectomy: SWOG S9921. J Clin Oncol 2018;36:1498–1504.
    1. Kellokumpu‐Lehtinen P‐LI, Hjälm‐Eriksson M, Astrom L et al. A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG‐13 trial. J Clin Oncol 2018;36(suppl 15):5000a.
    1. Thalgott M, Horn T, Heck MM et al. Long‐term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high‐risk prostate cancer. J Hematol Oncol 2014;7:20.
    1. Zhao B, Yerram NK, Gao T et al. Long‐term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy. Urol Oncol 2015;33(64):e19–e23.
    1. Siddiqui SA, Boorjian SA, Blute ML et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int 2011;107:383–388.
    1. Berglund RK, Tangen CM, Powell IJ et al. Ten‐year follow‐up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: Update on Southwest Oncology Group Study 9109. Urology 2012;79:633–637.
    1. Roberts E, Cossigny DA, Quan GM. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer 2013;2013:418340.
    1. Cheng P, Corzo CA, Luetteke N et al. Inhibition of dendritic cell differentiation and accumulation of myeloid‐derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008;205:2235–2249.
    1. Kujawski M, Kortylewski M, Lee H et al. Stat3 mediates myeloid cell‐dependent tumor angiogenesis in mice. J Clin Invest 2008;118:3367–3377.
    1. Di Lorenzo G, Figg WD, Fossa SD et al. Combination of bevacizumab and docetaxel in docetaxel‐pretreated hormone‐refractory prostate cancer: A phase II study. Eur Urol 2008;54:1089–1094.
    1. Atkins MB, Plimack ER, Puzanov I et al. Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). J Clin Oncol 2018;36(suppl 6):579a.
    1. Motzer RJ, Powles T, Atkins MB et al. IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018;36(suppl 6):578a.
    1. Atkins MB, Plimack ER, Puzanov I et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non‐randomised, open‐label, dose‐finding, and dose‐expansion phase 1b trial. Lancet Oncol 2018;19:405–415.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere